Still, the studys scale, duration and granular clinical data provide meaningful evidence to inform riskbenefit discussions. Balancing risks and benefits Importantly, the analysis assessed risk associated with initiation of semaglutide rather than cumulative dose or treatment duration. Whether risk varies by dosing intensity or length of exposure remains an open question
Research demonstrates that patients using semaglutide for weight management can achieve an average weight loss of 12-15% of their starting body weight over 68 weeks
Semaglutide# Semaglutide has the most extensive GLP-1 evidence base: SUSTAIN (T2D injectable, 7 trials), PIONEER (T2D oral, 9 trials), STEP (obesity, multiple trials), and SELECT (cardiovascular outcomes, n=17,604, 20% MACE reduction)
A clinical study showed that semaglutide (2.4 mg once weekly) reduced body weight by 10-15% of initial weight compared to 2-3% with placebo
Shima Hadidchi, MD, for Your Semaglutide GLP-1 Weight Loss Treatment